G. JERUSALEM Et Al. , "Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.," JAMA oncology , vol.4, pp.1367-1374, 2018
JERUSALEM, G. Et Al. 2018. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.. JAMA oncology , vol.4 , 1367-1374.
JERUSALEM, G., de, B., HURVITZ, S., YARDLEY, D., KOVALENKO, E., EJLERTSEN, B., ... BLAU, S.(2018). Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.. JAMA oncology , vol.4, 1367-1374.
JERUSALEM, G Et Al. "Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.," JAMA oncology , vol.4, 1367-1374, 2018
JERUSALEM, G Et Al. "Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.." JAMA oncology , vol.4, pp.1367-1374, 2018
JERUSALEM, G. Et Al. (2018) . "Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.." JAMA oncology , vol.4, pp.1367-1374.
@article{article, author={G JERUSALEM Et Al. }, title={Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.}, journal={JAMA oncology}, year=2018, pages={1367-1374} }